Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Revolution Medicines presented updated Phase 1/2 data for daraxonrasib in first-line metastatic pancreatic cancer, showing an objective response rate of 58% in combination with gemcitabine and nab-paclitaxel (GnP) and 47% as monotherapy. The safety profiles were described as manageable, with no Grade 5 treatment-related adverse events reported in the combination cohort and no Grade 4 or 5 events in the monotherapy cohort.
Key figures
- Drug Name
- daraxonrasib (RMC-6236)
- Phase Of Trial
- Phase 1/2
- Mono orr
- 47%
- Combo orr
- 58%
- Mono 6mo pfs
- 71%
- Combo 6mo pfs
- 84%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.